Did anyone else notice in the Q1 results out of Japan that they mentioned Covid could delay ongoing trials, presumably due to slowing of enrollment?
How big will the no-drug gap get in 2023/2024 before costs are contained?
How big will the no-drug gap get in 2023/2024 before costs are contained?